TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06979596: A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)

Sponsor: Merck Sharp & Dohme LLC · Phase: PHASE2 · Area: ONCOLOGY · Target Enrollment: 250 pts

Competing Trials Overlap

7 Active Trials

Excess Burn Exposure

$1,339,800

Rescue Site Savings

+$877,800

Unlock Full NCT06979596 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06979596 Rescue Dossier →